Medtech POV Blog

IEEPA Tariff Refunds Summary – What MedTech Companies Need to Know

Sally Laing and Devin Sikes, Partners, International Trade, Akin Gump provided an overview on April 29 of recent legal developments affecting IEEPA tariff refunds and walked members through how U.S. Customs and Border Protection (CBP) is implementing the refund process, including what companies should expect and practical considerations for participation.

Why Refunds Are Happening

Earlier this year, the U.S. Supreme Court ruled that the President did not have authority under IEEPA to impose tariffs. While the Court did not address refunds directly, the decision set in motion a court‑supervised process to return duties that had been collected under those tariffs.

As a result, CBP is now administering refunds covering a very large universe of affected imports—more than 300,000 importers and tens of millions of entries, representing a substantial amount of duty paid.

How Refunds Are Being Processed: The CAPE System

To manage this scale, CBP has created a new administrative mechanism called CAPE (Consolidated Administration and Processing of Entries), which operates within CBP’s existing Automated Commercial Environment (ACE).

Key characteristics of CAPE include:


Phase 1: What Is Eligible Now

Phase 1 covers a significant portion of affected entries, including:

Entries Not Covered Yet

Some entries are excluded from Phase 1 and are expected to be addressed in later phases, including:

CBP has not yet provided a timeline for when Phase 2 will begin, but officials have indicated future phases are coming and will expand coverage.

Who Can Submit Refund Requests

If a company relies entirely on a customs broker, coordination with that broker will be essential—especially if brokers are handling high volumes of refund requests.

How the Submission Process Works

CAPE submissions are relatively straightforward from a technical standpoint:

Once accepted, CBP removes the IEEPA tariff codes, recalculates duties, and applies standard review and liquidation procedures.

Timing, Refund Amounts, and Interest
Open Questions and Practical Considerations

The presenters emphasized that while the rollout has been faster and smoother than many expected, some important uncertainties remain, including:

They encouraged companies to begin by identifying “clean” entries eligible for Phase 1 and ensuring data is accurate before submission, particularly if more complex entries will require additional review later.

If you couldn’t attend the webinar live, watch the recording below to catch the highlights.

AdvaMed will continue to monitor IEEPA developments and provide member guidance as Phase 2 requirements are released. Stay turned for further updates from our team. Questions? Contact our team.


REMINDER: the information shared during the webinar, including the content of the slides, was current as of April 29, 2026 may be subject to change in the future. Please keep in mind that nothing discussed in this session should be considered legal advice. For any legal questions or guidance relating to your specific circumstances, you should always consult with your own legal counsel. Our goal is to provide helpful and up-to-date information, but your individual situation may require personalized legal advice.

Hear Patient Stories

The Story of Medtech empowers patients to share their experiences with medical technology in an effort to educate, inspire, and create community.

Become a member to continue reading. Join AdvaMed®

Sign in to access AdvaMed® member-only content.